Oprelvekin biosimilar - Xiamen Amoytop Biotech

Drug Profile

Oprelvekin biosimilar - Xiamen Amoytop Biotech

Alternative Names: Interleukin-11 - Xiamen Amoytop Biotech; Topmega

Latest Information Update: 04 Feb 2014

Price : $50

At a glance

  • Originator Xiamen Amoytop Biotech
  • Class Antineoplastics; Chemoprotectants; Interleukins; Recombinant proteins
  • Mechanism of Action Immunostimulants; Interleukin 11 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Thrombocytopenia

Most Recent Events

  • 12 Aug 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top